APO RESEARCH · REPORT
Immuno-Oncology
Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
Product & engineering
Understand the product.
Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
Selected research
Industry Research
Immuno-Oncology Industry Research Report 2026
Market perspective
Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
The industry's leading producers are Bristol-Myers Squibb, Merck & Co and Roche AG, with revenues of 27.89%, 22.10% and 20.85%, respectively, in 2019.
Report Scope
Read the full market overview
This report quantifies the global Immuno-Oncology market in terms of revenue (US$ million) and, where applicable, service volume (), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Immuno-Oncology.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Immuno-Oncology Market by Company
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Immuno-Oncology Segment by Type
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Others
Immuno-Oncology Segment by Application
Hospitals
Drugstores
Others
Immuno-Oncology Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immuno-Oncology market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Immuno-Oncology and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immuno-Oncology.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Immuno-Oncology companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Immune Checkpoint Inhibitors
- Cytokine-Based Immunotherapy
- Cancer Vaccines
- CAR-T Cell Therapy
- Others
Applications
- Hospitals
- Drugstores
- Others
Companies covered
- Bristol-Myers Squibb
- Merck & Co., Inc.
- Roche AG
- AstraZeneca, Plc
- Sanofi S.A.
- Dendreon Pharmaceuticals
- Novartis
- Gilead Sciences Inc.
- Merck KGaA
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Immuno-Oncology by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Immune Checkpoint Inhibitors
- 2.2.3 Cytokine-Based Immunotherapy
- 2.2.4 Cancer Vaccines
- 2.2.5 CAR-T Cell Therapy
- 2.2.6 Others
- 2.3 Immuno-Oncology by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Drugstores
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Immuno-Oncology Breakdown Data by Type
- 3.1 Global Immuno-Oncology Historic Market Size by Type (2021-2026)
- 3.2 Global Immuno-Oncology Forecasted Market Size by Type (2027-2032)
4 Immuno-Oncology Breakdown Data by Application
- 4.1 Global Immuno-Oncology Historic Market Size by Application (2021-2026)
- 4.2 Global Immuno-Oncology Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Immuno-Oncology Market Perspective (2021-2032)
- 5.2 Global Immuno-Oncology Growth Trends by Region
- 5.2.1 Global Immuno-Oncology Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Immuno-Oncology Historic Market Size by Region (2021-2026)
- 5.2.3 Immuno-Oncology Forecasted Market Size by Region (2027-2032)
- 5.3 Immuno-Oncology Market Dynamics
- 5.3.1 Immuno-Oncology Industry Trends
- 5.3.2 Immuno-Oncology Market Drivers
- 5.3.3 Immuno-Oncology Market Challenges
- 5.3.4 Immuno-Oncology Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Immuno-Oncology Players by Revenue
- 6.1.1 Global Top Immuno-Oncology Players by Revenue (2021-2026)
- 6.1.2 Global Immuno-Oncology Revenue Market Share by Players (2021-2026)
- 6.2 Global Immuno-Oncology Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Immuno-Oncology Head Office and Area Served
- 6.4 Global Immuno-Oncology Players, Product Type & Application
- 6.5 Global Immuno-Oncology Manufacturers Established Date
- 6.6 Global Immuno-Oncology Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Immuno-Oncology Market Size (2021-2032)
- 7.2 North America Immuno-Oncology Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Immuno-Oncology Market Size by Country (2021-2026)
- 7.4 North America Immuno-Oncology Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Immuno-Oncology Market Size (2021-2032)
- 8.2 Europe Immuno-Oncology Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Immuno-Oncology Market Size by Country (2021-2026)
- 8.4 Europe Immuno-Oncology Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Immuno-Oncology Market Size (2021-2032)
- 9.2 Asia-Pacific Immuno-Oncology Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Immuno-Oncology Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Immuno-Oncology Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Immuno-Oncology Market Size (2021-2032)
- 10.2 South America Immuno-Oncology Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Immuno-Oncology Market Size by Country (2021-2026)
- 10.4 South America Immuno-Oncology Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Immuno-Oncology Market Size (2021-2032)
- 11.2 Middle East & Africa Immuno-Oncology Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Immuno-Oncology Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Immuno-Oncology Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Bristol-Myers Squibb
- 12.1.1 Bristol-Myers Squibb Company Information
- 12.1.2 Bristol-Myers Squibb Business Overview
- 12.1.3 Bristol-Myers Squibb Revenue in Immuno-Oncology Business (2021-2026)
- 12.1.4 Bristol-Myers Squibb Immuno-Oncology Product Portfolio
- 12.1.5 Bristol-Myers Squibb Recent Developments
- 12.2 Merck & Co., Inc.
- 12.2.1 Merck & Co., Inc. Company Information
- 12.2.2 Merck & Co., Inc. Business Overview
- 12.2.3 Merck & Co., Inc. Revenue in Immuno-Oncology Business (2021-2026)
- 12.2.4 Merck & Co., Inc. Immuno-Oncology Product Portfolio
- 12.2.5 Merck & Co., Inc. Recent Developments
- 12.3 Roche AG
- 12.3.1 Roche AG Company Information
- 12.3.2 Roche AG Business Overview
- 12.3.3 Roche AG Revenue in Immuno-Oncology Business (2021-2026)
- 12.3.4 Roche AG Immuno-Oncology Product Portfolio
- 12.3.5 Roche AG Recent Developments
- 12.4 AstraZeneca, Plc
- 12.4.1 AstraZeneca, Plc Company Information
- 12.4.2 AstraZeneca, Plc Business Overview
- 12.4.3 AstraZeneca, Plc Revenue in Immuno-Oncology Business (2021-2026)
- 12.4.4 AstraZeneca, Plc Immuno-Oncology Product Portfolio
- 12.4.5 AstraZeneca, Plc Recent Developments
- 12.5 Sanofi S.A.
- 12.5.1 Sanofi S.A. Company Information
- 12.5.2 Sanofi S.A. Business Overview
- 12.5.3 Sanofi S.A. Revenue in Immuno-Oncology Business (2021-2026)
- 12.5.4 Sanofi S.A. Immuno-Oncology Product Portfolio
- 12.5.5 Sanofi S.A. Recent Developments
- 12.6 Dendreon Pharmaceuticals
- 12.6.1 Dendreon Pharmaceuticals Company Information
- 12.6.2 Dendreon Pharmaceuticals Business Overview
- 12.6.3 Dendreon Pharmaceuticals Revenue in Immuno-Oncology Business (2021-2026)
- 12.6.4 Dendreon Pharmaceuticals Immuno-Oncology Product Portfolio
- 12.6.5 Dendreon Pharmaceuticals Recent Developments
- 12.7 Novartis
- 12.7.1 Novartis Company Information
- 12.7.2 Novartis Business Overview
- 12.7.3 Novartis Revenue in Immuno-Oncology Business (2021-2026)
- 12.7.4 Novartis Immuno-Oncology Product Portfolio
- 12.7.5 Novartis Recent Developments
- 12.8 Gilead Sciences Inc.
- 12.8.1 Gilead Sciences Inc. Company Information
- 12.8.2 Gilead Sciences Inc. Business Overview
- 12.8.3 Gilead Sciences Inc. Revenue in Immuno-Oncology Business (2021-2026)
- 12.8.4 Gilead Sciences Inc. Immuno-Oncology Product Portfolio
- 12.8.5 Gilead Sciences Inc. Recent Developments
- 12.9 Merck KGaA
- 12.9.1 Merck KGaA Company Information
- 12.9.2 Merck KGaA Business Overview
- 12.9.3 Merck KGaA Revenue in Immuno-Oncology Business (2021-2026)
- 12.9.4 Merck KGaA Immuno-Oncology Product Portfolio
- 12.9.5 Merck KGaA Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst